SAN FRANCISCO, Dec. 19, 2018 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announces they will host
Participants in the conference and conference agenda will be announced in 2019. Potential presenters may include academic and industry leaders, such as uBiome board members Joseph Jimenez, former CEO of Novartis; Dr. Joseph DeRisi, MacArthur Genius Award winner; and advisory board members Dr. Pablo Valenzuela, PhD, Chief Executive Officer and President of Andes Biotechnologies; Dr. Atul Butte, MD, PhD, Director of the Institute of Computational Health Sciences at UCSF; Dr. David Agus, MD, Founding Director of USC's Lawrence J. Ellison Institute for Transformative Medicine; Dr. Philip Bourne, PhD, Director of the Data Science Institute at the University of Virginia; Dr. Peter Turnbaugh, PhD, Associate Professor of Microbiology and Immunology at UCSF; Dr. Purna Kashyap, MBBS, Mayo Clinic Gastroenterologist and Hepatologist; Dr. Sebastian Bernales, PhD, CEO & Co-founder, Praxis Biotech, LLC; and Dr. Jason Yamaki, PhD, PharmD, Assistant Professor in the School of Pharmacy at Chapman University as well as other thought leaders in this area.
"We are looking forward to hosting this event to tap into the expertise of industry leaders developing novel microbiome therapies focused on oncology, obesity, autoimmune disorders, and metabolic disorders," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "This conference serves as an example of our commitment to our mission of advancing the science of the microbiome and making it useful to people."
To learn more about uBiome's efforts, please visit https://ubiome.com/about-us/.
About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; SmartFlu™, the world's first sequencing-based clinical respiratory test, which identifies more than 20 clinically relevant targets for viruses and bacteria associated with the flu and common cold; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.
Subscribe to our Free Newsletters!